Urologic Cancers

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Prostate Cancer Vaccine Found Not To Improve Survival

Prostate Cancer Vaccine Found Not To Improve Survival

By

In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

By

Abiraterone plus leuprolide compared with leuprolide decreased the risk of biochemical recurrence by 38%.

Updated Analysis on Enfortumab Vedotin for Metastatic Urothelial Cancer

Updated Analysis on Enfortumab Vedotin for Metastatic Urothelial Cancer

Steven E. Benner, MD, discusses the updated analysis at the ASCO 2018 meeting in Chicago.

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

By

Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.

Novel FGFR3 Inhibitor May Be a New Treatment Option for Metastatic Urothelial Carcinoma

Novel FGFR3 Inhibitor May Be a New Treatment Option for Metastatic Urothelial Carcinoma

By

Previous early phase clinical studies have demonstrated that BGJ398 was active and well tolerated in a variety of FGFR-altered cancers.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Active Surveillance After Complete Response to Chemotherapy May Be Effective in Bladder Cancer

Active Surveillance After Complete Response to Chemotherapy May Be Effective in Bladder Cancer

By

Many patients are cured of all disease (pT0) post-chemotherapy and may be able to defer invasive surgery if properly identified.

Postresection intravesical instillation of gemcitabine decreases non-muscle-invasive urothelial cancer recurrence

In this randomized controlled trial, instilling postresection chemotherapy, specifically gemcitabine, was found to decrease tumor recurrence in non-muscle-invasive urothelial cancer when compared to saline treatment as a placebo.

Bladder Cancer, UTUC More Common in Kidney Transplant Recipients

Bladder Cancer, UTUC More Common in Kidney Transplant Recipients

By

A study found that bladder cancer and UTUC occurred in 122.22 and 113.97 per 100,000 persons per year, respectively, among kidney transplant recipients.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Neoadjuvant Dose-Dense Gemcitabine, Cisplatin May Be an Ideal Regimen in Bladder Cancer

Neoadjuvant Dose-Dense Gemcitabine, Cisplatin May Be an Ideal Regimen in Bladder Cancer

By

Various aspects of optimal treatment, such as optimal dose, drug combination, number of cycles, and duration of therapy have yet to be clearly defined for patients with bladder cancer.

Could Diet Adjustment Prevent Aggressive Prostate Cancer?

Could Diet Adjustment Prevent Aggressive Prostate Cancer?

By

A recent article is only the latest in a series of studies drawing attention to the importance of diet in prostate cancer development.

Online Survey May Allow Patients With Prostate Cancer To Accurately Report Comorbidities

Online Survey May Allow Patients With Prostate Cancer To Accurately Report Comorbidities

By

The BMH online survey allows patients to enter comorbidity data at home prior to consultation.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Testicular Cancer Treatment Regimens

Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Pembrolizumab Before Radical Cystectomy: Safe and Effective in Urothelial Carcinoma

Pembrolizumab Before Radical Cystectomy: Safe and Effective in Urothelial Carcinoma

By

One instance of grade 3 alanine aminotransferase elevation and 5 instances of reversible immune-related adverse events were observed.

FDA Approves Nivolumab With Ipilimumab for Renal Cell Carcinoma

FDA Approves Nivolumab With Ipilimumab for Renal Cell Carcinoma

By

Approval was based on results from the randomized phase 3 CheckMate-214 study.

Diet and Dosage: How Much Could Patients Save?

Diet and Dosage: How Much Could Patients Save?

By

Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.

Tumor Cell Lysate Vaccine Shows Promise

Tumor Cell Lysate Vaccine Shows Promise

By

Antigen-specific T cells increased in frequency in vaccinated mice.

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

By

The cause of death was prostate cancer among 18% vs 22% of patients receiving ADT vs ADT plus MP, respectively.

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

By

Results from the Prostate Cancer Prevention Trial indicate that the reduced risk for prostate cancer among men assigned to finasteride continued throughout 16 years of follow-up.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

By

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Low-Dose Abiraterone With Low-Fat Meals: Non-Inferior to Standard Dose

Low-Dose Abiraterone With Low-Fat Meals: Non-Inferior to Standard Dose

By

Patients in both treatment arms had a PFS of about 9 months.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs